Cytek Biosciences Files 8-K on Financial Condition & Results
Ticker: CTKB · Form: 8-K · Filed: Jan 9, 2024 · CIK: 1831915
| Field | Detail |
|---|---|
| Company | Cytek Biosciences, Inc. (CTKB) |
| Form Type | 8-K |
| Filed Date | Jan 9, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: financial-condition, results-of-operations, 8-K
TL;DR
**Cytek Biosciences just dropped an 8-K on financial results, get ready for updated numbers.**
AI Summary
Cytek Biosciences, Inc. filed an 8-K on January 9, 2024, reporting an event that occurred on January 8, 2024, related to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'. This filing indicates that the company is providing updated financial information, which is crucial for investors to understand Cytek's current financial health and operational performance. For stockholders, this matters because it offers a timely glimpse into the company's recent financial results, potentially influencing their investment decisions regarding CTKB stock.
Why It Matters
This filing signals that Cytek Biosciences is updating the market on its financial performance, which is essential for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial information, not indicating any immediate negative events or significant changes in company operations.
Analyst Insight
Investors should look for the actual financial results and exhibits that will be attached to this 8-K to understand the full impact on Cytek Biosciences' performance and stock value.
Key Players & Entities
- Cytek Biosciences, Inc. (company) — the registrant filing the 8-K
- January 8, 2024 (date) — date of the earliest event reported
- January 9, 2024 (date) — date the 8-K was filed
- CTKB (company) — trading symbol for Cytek Biosciences, Inc.
- Nasdaq Global Select Market (company) — exchange where Cytek Biosciences' common stock is registered
FAQ
What was the specific date of the earliest event reported in this 8-K filing by Cytek Biosciences, Inc.?
The earliest event reported in this 8-K filing by Cytek Biosciences, Inc. occurred on January 8, 2024.
What is the trading symbol for Cytek Biosciences, Inc. and on which exchange is its common stock registered?
The trading symbol for Cytek Biosciences, Inc. is CTKB, and its common stock is registered on the Nasdaq Global Select Market.
What are the specific items of information included in this 8-K filing?
The specific items of information included in this 8-K filing are 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'.
What is the business address of Cytek Biosciences, Inc. as stated in the filing?
The business address of Cytek Biosciences, Inc. is 47215 Lakeview Boulevard, Fremont, California, 94538.
What is the central index key (CIK) for Cytek Biosciences, Inc.?
The central index key (CIK) for Cytek Biosciences, Inc. is 0001831915.
Filing Stats: 495 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-01-09 06:05:00
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share CTKB Nasdaq Global Select
Filing Documents
- d690054d8k.htm (8-K) — 25KB
- d690054dex991.htm (EX-99.1) — 11KB
- 0001193125-24-004805.txt ( ) — 156KB
- ctkb-20240108.xsd (EX-101.SCH) — 3KB
- ctkb-20240108_lab.xml (EX-101.LAB) — 17KB
- ctkb-20240108_pre.xml (EX-101.PRE) — 11KB
- d690054d8k_htm.xml (XML) — 3KB
02
Item 2.02 Results of Operations and Financial Condition. On January 8, 2024, Cytek Biosciences, Inc. issued a press release announcing its preliminary unaudited revenue for the full year ended December 31, 2023. A copy of the press release is furnished herewith as Exhibit 99.1. The information furnished in this Current Report under Item 2.02 and the exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description of Exhibit 99.1 Press release dated January 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cytek Biosciences, Inc. Date: January 9, 2024 By: /s/ Wenbin Jiang Wenbin Jiang, Ph.D. President and Chief Executive Officer